Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history
| Autor: | Benoît Soubeyrand, Pierre Lebon, Odile Launay, Charles Baptiste, Corinne Desaint, Lionel Desforges, Nicole Guiso, Sylvie Larnaudie |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Vaccination schedule Diphtheria Toxoid Immunology Immunization Secondary Antibodies Viral Young Adult medicine Tetanus Toxoid Humans Prospective Studies Vaccines Combined General Pharmacology Toxicology and Pharmaceutics Diphtheria-Tetanus-Pertussis Vaccine Immunization Schedule Pertussis Vaccine business.industry Tetanus Diphtheria Vaccination Antibody titer Middle Aged medicine.disease Antibodies Bacterial Poliomyelitis Poliovirus Vaccines Poliovirus Vaccine Inactivated Immunization Humoral immunity Female France business |
| Zdroj: | Human vaccines. 6(10) |
| ISSN: | 1554-8619 |
| Popis: | This study was to assess the humoral immune response induced by a vaccination schedule routinely used in France in 18-50 year old adults with unknown vaccination history. In this monocentric, prospective study, subjects received one dose of REVAXIS® (dT-IPV, diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)) (Visit 1) followed by one dose of REPEVAX® (dTap-IPV, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)) one month later (Visit 2). Antibodies against diphtheria, tetanus, poliomyelitis types 1, 2 and 3, and pertussis toxin (PT) were measured one month after the administration of REPEVAX® (Visit 3). A total of 136 subjects were included in the study, but blood samples were available for only 73 subjects. Their mean age at inclusion was 33.2 ± 7.3 years. 49.3% of the 73 subjects originated from the WHO African Region, 6.8% from the WHO Western Pacific Region and 5.5% from the WHO European Region. One month after REPEVAX® administration, all subjects had seroprotective antibody titers against diphtheria and tetanus (≥0.1 IU/mL), poliomyelitis types 2 and 3 (≥ 8 1/dil); one subject (1.4%) did not have antibodies against poliomyelitis type 1. The rate of anti-PT seropositivity (≥8 EU/mL) was 94.4%. One dose of REPEVAX® administered one month after a dose of REVAXIS® in subjects with unknown vaccination history induced a high humoral response. These results validate a vaccination schedule routinely used for years that rapidly elicits effective immunization against diphtheria, tetanus, poliomyelitis and pertussis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|